Σφακιανάκης Αλέξανδρος
ΩτοΡινοΛαρυγγολόγος
Αναπαύσεως 5 Άγιος Νικόλαος
Κρήτη 72100
00302841026182
00306932607174
alsfakia@gmail.com

Αρχειοθήκη ιστολογίου

! # Ola via Alexandros G.Sfakianakis on Inoreader

Η λίστα ιστολογίων μου

Παρασκευή 20 Απριλίου 2018

Effects of Etanercept on the Patient-Perceived Results (PROs) in Patients with Moderate-To-Severe Plaque Psoriasis: Systematic Review of the Literature and Meta-Analysis.

Related Articles

Effects of Etanercept on the Patient-Perceived Results (PROs) in Patients with Moderate-To-Severe Plaque Psoriasis: Systematic Review of the Literature and Meta-Analysis.

J Dermatolog Treat. 2018 Apr 19;:1-20

Authors: Carrascosa JM, Rebollo F, Gómez S, de la Cueva P

Abstract
PURPOSE: To evaluate the efficacy of etanercept (ETN) compared with placebo for moderate-to-severe psoriasis regarding patients reported outcomes (PROs).
METHODS: Systematic review of studies retrieved by a sensitive search strategy in Medline, Embase, Cochrane Library.
SELECTION CRITERIA: (population) studies had to include patients with for moderate-to-severe psoriasis; (intervention and control) studies had to test ETN vs placebo; and (outcomes), studies had to report PROs including quality of life, pain, pruritus or sleep. Only randomized controlled trials (RCT) were included. Two reviewers independently selected the articles and collected data. Studies quality was assessed using the Jadad score. For the meta-analysis, a random effects model was followed and statistical heterogeneity was tested with statistic I2.
RESULTS: We finally included 12 RCT. Compared with placebo, ETN significantly improved quality of life, patient global assessment, pruritus and pain in the short and medium term, fatigue in the short term (although the effect size and differences with placebo are unclear). ETN also produces a high patient's satisfaction, which increases over time and is higher compared with placebo and might improve depressive symptoms in the long term.
CONCLUSIONS: ETN is an effective option for improving PROs in patients with moderate-to-severe psoriasis.

PMID: 29671665 [PubMed - as supplied by publisher]



https://ift.tt/2JbVrNY

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Αρχειοθήκη ιστολογίου